Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

by

Homepage
Tags search
Teva Pharmaceutical Industries

CTech 24/7

More stories in CTech

Teva Pharmaceutical Industries

26 stories about Teva Pharmaceutical Industries

Analysis: Teva Pharmaceuticals is bogged down by legal issues, fails to kick-start growth
08.11.20|Sophie ShulmanCEO Kare Schultz managed over the past three years to keep the boat steady and lessen its debt, but slow growth won’t satisfy investors
For foreign companies, understanding China’s annual plans is critical
12.10.20|Tslil Kleiman Chinese governmental programs not only define what is “forbidden” and “allowed,” but also determine to which regions and industries investments will be directed, and which projects will be given priority
Teva is recruiting Israeli academia to help produce its next breakthrough drug
13.09.20|CTechYou reap what you sow: The pharmaceutical giant is partnering up with researchers to try and find the next Copaxone
A renaissance of entrepreneurship and innovation is our chance to withstand the Covid-19 challenge
23.08.20|Assaf WeissThe global crisis presents us with a load of new opportunities for online activities in the fields of commerce, education, work, and leisure
Teva Gets Fresh Cash, Fresh Woes
04.02.18|Dror ReichAfter the troubled drugmaker finalized two deals that will enable it to repay some of its debt, S&P placed it on CreditWatch negative on Friday
Following U.S. Bribe Settlement, Teva to Pay $22 Million Fine in Israel
15.01.18|Tomer GanonYesterday, the Israeli state attorney settled a suit against the company. In 2016, Teva agreed to pay $519 million to settle anti-bribery violations in the U.S.
Moody’s Downgrades Teva Bond Rating to “Junk”
14.01.18|Lilach BaumerThe credit rating agency is following is the steps of Fitch, which did the same in November. Of the “big three,” only S&P Global still rates Teva as investment grade
After Announcing Restructuring Plan, Teva's Board of Directors Takes Paycut
11.01.18|Lilach BaumerIn December, the generic drugmaker announced a plan to let go 14,000 employees
As Part of Cost-Cutting Plan, Teva Will Shut Down Twenty or More Manufacturing Sites
10.01.18|Lilach BaumerThe drugmaker will shut down 20-25 manufacturing sites in the next two years, CEO Kåre Schultz said Monday
Teva CEO to Netanyahu: Layoffs will Proceed as Planned
19.12.17|Omri MilmanIn a statement, the company said it rejects the Israeli government’s appeal to withdraw cutback plans
Following Restructuring Announcements, Teva Reinstated as Israel’s Biggest Company
18.12.17|Lilach BaumerTeva's stock jumped 18.7% on the New York Stock Exchange between Thursday market opening and Friday market close. Israeli Prime Minister Benjamin Netanyahu is expected to meet with CEO Kåre Schultz Tuesday
Teva Might Have Been Better Off as a Smaller Company, new CEO Says
17.12.17|Dror ReichThe generic drugs powerhouse is now carrying a $34.7 billion debt—a result of a $40.5 acquisition of Actavis. New CEO Kåre Schultz presented a detailed restructuring plan on Thursday
Tel Aviv Airport, Stock Market Open as Solidarity Strike Ends
17.12.17|Lior Gutman, Omri Milman and Micky GrunfeldIsrael’s largest labor union called for a half-day strike on Thursday, in support of Teva employees
Once Future CEO Could have Taken Teva on a Different Path
14.12.17|Lilach Baumer, Golan Hazani, and Orr HirschaugeAstraZeneca CEO Pascal Soriot, which backed out of Teva’s CEO position in July, planned on taking the company towards innovation instead of generic focus
Teva to Cut Around Half of Israeli Workforce, Outsource Operations
13.12.17|Dror ReichAn internal document reviewed by Calcalist reveals the troubled drugmaker's detailed domestic cost-cutting plans
Teva to Cut Jobs, Shut Down Some Israeli Operations
13.12.17|Dror Reich and Sefi KrupskyOn Thursday, the troubled drugmaker is expected to unveil its cutback plan. At its center is extensive layoffs and the reorganization and divestment of non-core assets
Former Chairman Yitzhak Peterburg Leaves Teva
13.12.17|Lilach BaumerMr. Peterburg was the troubled drugmaker's interim CEO between February and November 1, when Kåre Schultz took helm
Teva to Unveil Strategic Plan, Layoffs Thursday
12.12.17|Dror ReichLast month the debt-riddled drug maker announced a rehabilitation plan amidst rumors of upcoming employee cuts
Teva’s Stock Jumps Following Report on Planned Cuts
10.12.17|Dror Reich and Lilach BaumerOn Friday, Bloomberg reported that Teva might be slashing as many as 10,000 jobs, citing sources. Last month, Calcalist reported Teva is planning to cut over 4,000 jobs in the U.S. and Israel
Fresh Teva Lawsuit Goes Against Dividends Paid by Debt Heavy Drugmaker
30.11.17|Anat RouahTel Aviv-based capital investment firm Tulip Capital is threatening derivative action against Teva, saying the company's huge debt load renders its dividends unlawful

About CTech Terms of Use Privacy Policy

Back to Top